future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.
Transgenomic, Inc.
Summary Financial Results
Unaudited Condensed Consolidated Statements of Operations
(dollars in thousands except per share data)
Three Months Ended Year Ended
December 31, December 31,
2008 2007 2008 2007
---- ---- ---- ----
NET SALES $6,126 $6,531 $23,993 $23,176
COST OF GOODS SOLD 2,776 2,610 10,345 10,483
Gross profit 3,350 3,921 13,648 12,693
OPERATING EXPENSES:
Selling, general and
administrative 1,972 2,748 10,795 11,466
Research and development
'/>"/>
SOURCE Transgenomic, Inc. Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related biology technology :1.
Transgenomic, Inc. Reports Second Quarter 2007 Results2.
Transgenomic, Inc. Forms Scientific Advisory Board3.
Transgenomic, Inc. Reports Third Quarter 2008 Results4.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound5.
QMed, Inc. Reports July Medicare SNP Enrollments6.
Phlo Affiliate Reports Expanded Coverage to Oregon Border7.
Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results8.
Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 20079.
Carrington Reports Second Quarter 2007 Results10.
Avitar Reports Third Quarter Financial Results for Fiscal 200711.
Response Genetics Reports Second Quarter 2007 Financial Results